---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277515"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:57:44.049489+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210

## Summary
- Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.
- Net loss for Q3 2025 was $6.0M, down from $11.9M in Q3 2024.
- R&D expenses decreased 32% to $4.0M; G&A decreased 43% to $2.2M due to cost reductions.
- Planning confirmatory Phase 3 trial of LYR-210 for CRS without nasal polyps following FDA meeting.
- Presented positive ENLIGHTEN 2 Phase 3 results at AAO-HNS meeting in October 2025.

## SEC filing metadata
- accession: 0001193125-25-277515
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/0001193125-25-277515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/lyra-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277515
- JSON: https://secwatch.observer/filing/0001193125-25-277515.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277515.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.